首页> 外文期刊>Science translational medicine >Up-Regulation of PD-L1, IDO, and T_(regs) in the Melanoma Tumor Microenvironment Is Driven by CD8~+ T Cells
【24h】

Up-Regulation of PD-L1, IDO, and T_(regs) in the Melanoma Tumor Microenvironment Is Driven by CD8~+ T Cells

机译:黑色素瘤肿瘤微环境中PD-L1,IDO和T_(regs)的上调受CD8〜+ T细胞的驱动

获取原文
获取原文并翻译 | 示例
           

摘要

Tumor escape from immune-mediated destruction has been associated with immunosuppressive mechanisms that inhibit T cell activation. Although evidence for an active immune response, including infiltration with CD8~+ T cells, can be found in a subset of patients, those tumors are nonetheless not immunologically rejected. In the current report, we show that it is the subset of T cell-inflamed tumors that showed high expression of three defined immunosuppressive mechanisms: indoleamine-2,3-dioxygenase (IDO), PD-L1/B7-H1, and FoxP3~+ regulatory T cells (T_(regs)), suggesting that these inhibitory pathways might serve as negative feedback mechanisms that followed, rather than preceded, CD8~+ T cell infiltration. Mechanistic studies in mice revealed that up-regulated expression of IDO and PD-L1, as well as recruitment of T_(regs), in the tumor microenvironment depended on the presence of CD8~+ T cells. The former was driven by interferon-gamma and the latter by a production of CCR4-binding chemokines along with a component of induced proliferation. Our results argue that these major immunosuppressive pathways are intrinsically driven by the immune system rather than being orchestrated by cancer cells, and imply that cancer immunotherapy approaches targeting negative regulatory immune checkpoints might be preferentially beneficial for patients with a preexisting T cell-inflamed tumor microenvironment.
机译:从免疫介导的破坏中逃脱的肿瘤与抑制T细胞活化的免疫抑制机制有关。尽管可以在一部分患者中发现主动免疫反应的证据,包括CD8 + T细胞的浸润,但是这些肿瘤仍未被免疫排斥。在本报告中,我们显示出T细胞发炎的肿瘤的子集显示了三种定义的免疫抑制机制的高表达:吲哚胺-2,3-双加氧酶(IDO),PD-L1 / B7-H1和FoxP3〜 +调节性T细胞(T_(regs)),表明这些抑制途径可能是CD8〜+ T细胞浸润之后而非之前的负反馈机制。对小鼠的机理研究表明,肿瘤微环境中IDO和PD-L1的表达上调以及T_(regs)的募集取决于CD8〜+ T细胞的存在。前者是由干扰素-γ驱动的,后者是由CCR4结合趋化因子的产生以及诱导增殖的成分驱动的。我们的研究结果表明,这些主要的免疫抑制途径本质上是由免疫系统驱动的,而不是由癌细胞精心策划的,这意味着针对阴性调节免疫检查点的癌症免疫疗法可能对患有T细胞炎症的肿瘤微环境的患者优先受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号